Hígado y hepatitis C en los adultos mayores. Opciones de tratamiento

Saturnino Jose Fernandez

Resumen


Los pacientes ancianos con hepatitis crónica por virus C sin evidencia de cirrosis en general se manejan expectante, sin el tratamiento combinado establecido de interferones pegilados alfa y ribavirina, ya que es poco probable que la vida se vea comprometida por su enfermedad hepática. Además, frecuentemente presentan co-morbilidad que puede afectar su sobrevida antes de que se presente descompensación hepática. El tratamiento en la población de adultos mayores, permanece como un asunto controversial, con evidencias limitadas. Las recomendaciones para el tratamiento de la población general están basadas sobre estudios multicéntricos, controlados y randomizados. Se ha evaluado el efecto de la edad sobre el tratamiento de pacientes con hepatitis crónica C con interferón pegilado alfa más ribavirina, se encontró que los pacientes mayores de 40 años, tuvieron menor oportunidad de observar respuesta virológica sostenida, comparado con pacientes más jóvenes. Los pacientes entre las edades 40-49, 50-64, y mayores de 65 años, demostraron bajas tasas de respuesta virológica sostenida. Todavía no está claro si la eficacia del interferón pegilado alfa y la ribavirina en pacientes con VHC mayores de 65 años, es la misma o peor que para pacientes en el grupo de 40 a 65 años. En los pacientes mayores de 65 años todavía no hay acuerdo sobre el tratamiento con la terapia doble o triple.

Palabras clave


Hepatitis C, ancianos, interferón, ribavirina, terapia doble, terapia triple.

Texto completo:

PDF

Referencias


Junaidi O, Di Bisceglie A. Aging Liver and Hepatitis. Clin Geriatr Med 2007;23:889-903.

Idrovo V. Hepatitis en ancianos. Rev Col Gastroenterol 2004;19 (4):2.

Brind AM, Watson JP, James OFW, et al. Hepatitis C virus infection in the elderly. QJM 1996;89:291-6.

Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. American Association for the Study of Liver Diseases. Hepatology 2004;39:1147-71.

Altera MJ. Epidemiology of hepatitis C. Hepatology 1997; 26(Suppl 1):62S-5S.

Carrion A, Martin P. Viral Hepatitis in the Elderly. Am J Gastroenterol. 2012;107(5):691-697.

Monica F, Lirussi F, Nassuato G, et al. Hepatitis C virus infection and related chronic liver disease in a resident elderly population: The Silea study. J Viral Hepat 1998; 5:345–51.

Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. American Association for the Study of Liver Diseases. Hepatology 2004;39:1147-71.

Gordon SC, Elloway RS, Long JC, et al. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 1993;18:1338-43.

Yano M, Yatsuhashi H, Inokuchi K, et al. Epidemiology and long term prognosis off hepatitis C virus infection in Japan. Gut 1993;34 (Suppl 1):S13-6.

Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.

Roudot-Thoraval F, Bastie A, Pawlotsky JM, et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997;26:485-90.

Floreani A, Bertin T, Soffiati G, et al. Anti-hepatitis C virus in the elderly: a seroepidemiological study in a home for the aged. Gerontology 1992;38:214-6.

Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon a-2b plus ribavirin compared with interferon a-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65.

Strader DB. Understudied populations with hepatitis C. Hepatology 2002;36(Suppl 1):S226-36.

Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon a-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.

Horiike N, Masumoto T, Nakanishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 1995;10:246-9.

Marcus EL, Tur-Kaspa R. Viral hepatitis in older adults. J Am Geriatr Soc 1997;45:755-63.

Bacosi M, Russo F, Dinnocenzo S, et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatol Res 2002;22:231-9.

Alessi N, Freni MA, Spadaro A, et al. Efficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis C. Infez Med 2003;11:208-12.

Imai Y, Kasahara A, Tanaka H, et al. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. J Gastroenterol 2004;39:1069-77.

Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105-14.

Thabut y colaboradores Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006;101(6):1260-7.

Arias E. United States life tables, 2002. Natl Vital Stat Rep 2004;53:1-38. 63-268.

Huang CF, Yang JF, Dai CY, Huang JF, Hou NJ, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL, Yu ML. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis. 2010; 201(5):751-9.

Teoh NC, Farrell GC, Chan HL. Individualization of antiviral therapy for chronic hepatitis C. J Gastroenterol Hepatol. 2010;25(7):1206-16.

Kogure T, et al. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. World J Gastroenterol 2008; 14(47): 7225-7230.

McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitIs C. Gastroenterology.2002;123:1061–9.

Shiffman ML, DiBisceglie A, Karen AM, Lindsay L, Morishima C, Wrigh EC, et al. Peginterferon alfa-2a and ribavirinin patients with chronic hepatitis C who have failed prior treatment. Gastroenterology.2004;126:1015-23.

Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, et al. Peginterferon alfa-2a and Ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. New Engl J Med 2007;357:124-134.

Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.

Skowronski M, Zozulinska D, Juszczyk J, Wierusz-Wysocka B. Hepatitis C virus infection: Evidence for an association with type 2 diabetes. Diabetes Care 2006;29:750-751.

Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-848.

Asselah T, Rubbia-Brandt L, Marcellin P, et al. Steatosis in chronic hepatitis C: Why does it really matter? Gut 2006;55: 123-30.

Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134:416-23.

Lee CM, Lu SN, Hung CH, et al. Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications. Trans R Soc Trop Med Hyg 2006;100:767-774.

Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P. Shortened treatment duration in treatment naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol 2010;52:25-31.

Rosen H. Chronic Hepatitis C Infection. N Engl J Med 2011; 364:2429-2438.

Bhala N, et al. The Natural History of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis or Cirrhosis: An International Collaborative Study. Hepatology 2011;54:1208-1216.

Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444-51.

Zeuzem S, Fried MW, Reddy KR, et al. Improving the clinical relevance of pretreatment viral load as a predictor of sustained virological response (SVR) in patients infected with Hepatitis C genotype 1 treated with peginterferon ALFA-2A (40KD) (PEGASYS ®) plus ribavirin (COPEGUS®) Hepatology 2006;44(Suppl 1):A267.

Kao JH, Lai MY, Chen PJ, et al. Clinical significance of serum hepatitis C virus titers in patients with chronic type C hepatitis. Am J Gastroenterol 1996;91:506-510.

Horiike N, Masumoto T, Nakanishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 1995;10:246-249.

Bresci G, Del Corso L, Romanelli AM, et al. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis. J Am Geriatr Soc 1993;41:857-862.

Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-641.

Conry-Cantilena C, Van Raden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-96.

Haber MM, West AB, Haber AD, Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995;90:1250-57.

Shakil AO, Conry-Cantelina C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, et al. Volunteer blood donors with antibody to hepatitis C virus: Clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995;123:330-37.

Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.

Gupta R, Ramakrishna CH, Lakhtakia S, Tandan M, Banerjee R, Reddy N. Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C. World J Gastroenterol 2006;12(34): 5554-5556.

Heathcote EJ, Keeffe EB, Lee SS, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136- 1143.

Lindsay KL, Trepo C, Heintges T, et al. A randomized, double blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.

Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-438.

Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007;46:371-379.

Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol 2006;62:699-709.

Takaki S, Tsubota A, Hosaka T, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alpha2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2004;39:668-673.

Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa treatment of anemic HCV-infected patients allows for maintenance of ribavirin dose, increases hemoglobin levels and improves quality of life vs. placebo: A randomized, double-blind, multi-center study. Gastroenterology 2003;124:714.

Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol 2007;102(7):1383-1391.

Yu J, Sun L, Kang P, Yan B-Z, Zhao Y. Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C. Hepatobiliary & Pancreatic Diseases International 2012;11( 2):185-192.

Marcus EL, Tur-Kaspa R. Chronic hepatitis C virus infection in older adults. Clin Infect Dis 2005;41:1606-1612.

Gupta SK, Glue P, Jacobs S, et al. Single-dose pharmacokinetics and tolerability of pegylated interferon alpha2b in young and elderly healthy subjects. Br J Clin Pharmacol 2003;56:131-134.

Martin NE, Modi MW, Reddy KR. Characterization of pegylated (40 kDa) interferon alfa-2a (PEGASYS) in the elderly. Hepatology 2000;32(4 pt 2):348A.

Matthews SJ, McCoy C. Peginterferon alfa-2a: A review of approved and investigational uses. Clin Ther 2004;26:991-1025. [ Links ]

Van Thiel DH, Friedlander L, Caraceni P, et al. Treatment of hepatitis C virus in elderly persons with interferon alpha. J Gerontol A Biol Sci Med Sci 1995;50:M330-M333.

Horiike N, Masumoto T, Nakanishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 1995;10:246-249.

McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.

Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996;24:778-789.

Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct acting antiviral agents for the treatment of hjepatitis C virus infection and perspectives. Gut 2012; 61 (suppl 1) : i36-i46.

Ghany MG, Nelson DR, Strader DR, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1434-44.

Molina E, Fernández J, Domínguez E. Indicaciones actuales de tratamiento triple para la hepatitis C. Gastroenterol Hepatol 2012;35(4):266-277.




DOI: http://dx.doi.org/10.61155/gen.v67i4.171

VIDEOS GEN



Pseudoquiste pancreático postraumático y Síndrome del Ducto Pacreático Desconectado.
Autor: Dr. Freddy Pereira Graterol

CPRE. Sitio de sección del ducto pancreático principal

Drenaje transgástrico de pseudoquiste pancreático

CPRE. Sección del ducto hepático izquierdo por traumatismo de abdomen





Cavernomatosis portal y colangiopatía portal. A propósito de un caso.
Autora: Dra. Anais Karina García Yaraure
 

Cavernomatosis portal Pre Colocacion de TIPS.

 

Cavernomatosis portal Post Colocacion de TIPS.




 

 

 

 

 

 

LatindexSciELOCrossref

Revista GEN
ISSN: 0016-3503 e-ISSN: 2477-975X
Depósito Legal: pp197602CS570
Sociedad Venezolana de Gastroenterología
Este trabajo está licenciado bajo Creative Commons 4.0.
Revista GEN no almacena ningun tipo de cookies ni variables de sesion de usuarios